# Magnesium Treating Subarachnoid Hemorrhage Vasospasm

Study · id `cardio:ct-nct04613960` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04613960](<https://clinicaltrials.gov/study/NCT04613960>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04613960

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT04613960. Randomized; quadruple masking; primary purpose prevention. Start 2022-12 (anticipated); primary completion 2023-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 2/3
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT04613960, source copy `cardio:ctgov-nct04613960-2022-09-13`, retrieved 2026-10-31)
- Planned start: 2022-12 (anticipated) (ClinicalTrials.gov record NCT04613960, source copy `cardio:ctgov-nct04613960-2022-09-13`, retrieved 2026-10-31)
- Primary completion: 2023-12 (anticipated) (ClinicalTrials.gov record NCT04613960, source copy `cardio:ctgov-nct04613960-2022-09-13`, retrieved 2026-10-31)
- Completion: 2024-06 (anticipated) (ClinicalTrials.gov record NCT04613960, source copy `cardio:ctgov-nct04613960-2022-09-13`, retrieved 2026-10-31)
- Countries: Egypt (ClinicalTrials.gov record NCT04613960, source copy `cardio:ctgov-nct04613960-2022-09-13`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04613960-2022-09-13`, retrieved 2026-10-31)

## The registry's words

- Brief title: Magnesium Treating Subarachnoid Hemorrhage Vasospasm
- Acronym: MATSH-SHapE
- Condition: Subarachnoid Hemorrhage, Aneurysmal
- Condition: Cerebral Vasospasm
- Intervention (Drug): Magnesium sulfate
- Intervention (Drug): normal saline
- Lead sponsor: General Committee of Teaching Hospitals and Institutes, Egypt
- Lead sponsor class: OTHER\_GOV
- Collaborator: Ain Shams University
- Collaborator class: OTHER
- Collaborator: Health Insurance Organization, Egypt
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Subarachnoid hemorrhage (`cardio:subarachnoid-hemorrhage`)
- Registry lists this organization as a collaborator: Ain Shams University (`cardio:org-ain-shams-university`)

## Provenance

Content hash: 194358fd029dbf2edb37d53d15fc2340c293dd7cc4db3513ecc9af7abb37e8a6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
